Edoxaban: prevenció de l'ictus i de l'embòlia sistèmica en pacients adults amb fibril.lació auricular no valvular amb almenys un factor de risc
Abstract
Edoxaban is the third direct inhibitor of factor X marketed in Spain. In the main clinical trial, it has shown similar efficacy in the prevention of stroke or systemic embolism and a reduction in serious haemorrhages compared to warfarin therapy. As in the rest of ACOD, it has been associated with less intracranial haemorrhages than AVK haemorrhages per year, less for every 1,000 European patients treated in the study. However, treatment with ouxaban has been associated with a greater risk of gastrointestinal haemorrhage.
Keywords
Edoxaban; Vitamin K antagonists; Direct oral anticoagulants
Bibliographic citation
Edoxaban: prevenció de l'ictus i de l'embòlia sistèmica en pacients adults amb fibril.lació auricular no valvular amb almenys un factor de risc. Barcelona: Servei Català de la Salut; 2017.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/3461This item appears in following collections
The following license files are associated with this item: